Last reviewed · How we verify
Thymus Tissue for Transplantation
At a glance
| Generic name | Thymus Tissue for Transplantation |
|---|---|
| Also known as | IND 9836, Thymus Tissue Transplant |
| Sponsor | Sumitomo Pharma Switzerland GmbH |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Expanded Access Protocol Thymus Transplantation (PHASE4)
- Thymus Transplantation Safety-Efficacy (NA)
- A New Surgical Strategy to Protect the Inferior Parathyroid (NA)
- Parathyroid and Thymus Transplantation in DiGeorge #931 (PHASE1)
- Thymus Transplantation With Immunosuppression (PHASE1)
- Serum-Free Thymus Transplantation in DiGeorge Anomaly (PHASE1)
- Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation (PHASE1)
- Thymus Transplantation Dose in DiGeorge #932 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thymus Tissue for Transplantation CI brief — competitive landscape report
- Thymus Tissue for Transplantation updates RSS · CI watch RSS
- Sumitomo Pharma Switzerland GmbH portfolio CI